Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Precision BioSciences Inc . (NASDAQ:DTIL), a profitable gene editing company with a market capitalization of $38.7 million, has announced the retirement of Dr. Sam Wadsworth from its Board of ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

SQZ Biotechnologies (NYSE:SQZ – Get Free Report) and Precision BioSciences (NASDAQ:DTIL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast ...

CARLSBAD, Calif. - Tyra Biosciences , Inc. (NASDAQ:TYRA), a biotech firm specializing in precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment ...

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $30.00. Discover outperforming stocks and invest smarter ...

BMO Capital upgraded Precision BioSciences (DTIL) to Outperform from Market Perform with an unchanged price target of $34 alter iECURE announced clinical data in ornithine transcarbamylase using ...

On Friday, BMO Capital Markets analysts upgraded Precision BioSciences Inc . (NASDAQ: NASDAQ:DTIL) stock rating from Market Perform to Outperform, setting a price target of $34.00. This optimistic ...

Precision BioSciences Inc . (NASDAQ:DTIL), a biotechnology company specializing in genome editing with a market capitalization of $36.74 million, has provided a preliminary financial update ...

Precision BioSciences (NASDAQ:DTIL) added ~26% in the morning hours on Friday after the gene-editing company said ECUR-506, one of its lead candidates, generated a complete clinical response in a ...